Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMI:TSE International Medical Innovations Inc. -- Ignore unavailable to you. Want to Upgrade?

To: gg cox who wrote (14)	11/11/2002 2:21:47 PM
From: gg cox	Read Replies (1) \| Respond to of 66

IMI to report third-quarter results and present at SG Cowen Global Healthcare Conference Monday November 11, 10:24 am ET IMI to host third-quarter webcast November 18 at 10:30 a.m. EST TORONTO, Nov. 11 /CNW/ - Predictive medicine company IMI International Medical Innovations Inc. (TSX:IMI - News) will be among the presenting companies at this week's SG Cowen Global Healthcare Conference in Paris. Dr. Brent Norton, IMI President and CEO, will give IMI's presentation to European institutional investors at 3:30 p.m. local time (9:30 a.m. EST) Wednesday, November 13. Dr. Norton will provide an overview of IMI's progress and opportunities for commercialization of its cardiovascular and cancer products. Third-quarter report and webcast IMI will report its fiscal 2002 third-quarter financial and operating results (for the period ended September 30, 2002) on Monday, November 18. The Company will host a webcast and conference call to review the results and update listeners on IMI's clinical, regulatory, and partnering activities. The webcast and conference call, which will be open to the general public, will be chaired by IMI's President and CEO, Dr. Brent Norton, and will include Ron Hosking, Vice-President and Chief Financial Officer, and Andrew Weir, Director, Communications. Date: Monday, November 18, 2002 Time: 10:30 a.m. Eastern Time Live webcast: www.imimedical.com Conference Call Numbers: (416) 405-9328 (Toronto area) (800) 387-6216 (North America toll free) Please call five minutes prior to the start time and specify the IMI call chaired by Dr. Brent Norton. Following its completion, a replay of the call can be accessed for three months on the Investor page of IMI's web site (www.imimedical.com), or for one week by dialing (416) 695-5800 or (800) 408-3053 (U.S. & Canada) and entering access code 1306686. IMI is a world leader in predictive medicine, dedicated to developing innovative products for the rapid and early detection of life-threatening conditions, particularly cardiovascular disease and cancer. The Company's lead products are Cholesterol 1,2,3(TM), a three-minute test that measures cholesterol on the skin, ColorectAlert(TM), a test for early-stage colorectal cancer and LungAlert(TM), a test for lung cancer. This release contains forward-looking statements that reflect the company's current expectation regarding future events. The forward-looking statements involve risk and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly filings. For further information Andrew Weir, Director, Communications, (416) 222-3449 x27, aweir@imimedical.com Richard Land, Karin Oloffson, Jaffoni & Collins Inc., (212) 835-8500, imi@jcir.com biz.yahoo.com